Human Genome Epidemiology Literature Finder
Records 1 - 15 (of 15 Records) |
Query Trace: CCDC6[original query] |
---|
Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma. Proceedings of the National Academy of Sciences of the United States of America 2008 May 105 (20): 7269-74. Jazdzewski Krystian, Murray Elizabeth L, Franssila Kaarle, Jarzab Barbara, Schoenberg Daniel R, de la Chapelle Albe |
Comprehensive analysis of targetable oncogenic mutations in chinese cervical cancers. Oncotarget 2015 Mar 6 (7): 4968-75. Xiang Libing, Li Jiajia, Jiang Wei, Shen Xuxia, Yang Wentao, Wu Xiaohua, Yang Huiju |
Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches. Clinical cancer research : an official journal of the American Association for Cancer Research 2015 1 21 (16): 3631-9. Drilon Alexander, Wang Lu, Arcila Maria E, Balasubramanian Sohail, Greenbowe Joel R, Ross Jeffrey S, Stephens Phil, Lipson Doron, Miller Vincent A, Kris Mark G, Ladanyi Marc, Rizvi Naiyer |
USP7 inhibitors, downregulating CCDC6, sensitize lung neuroendocrine cancer cells to PARP-inhibitor drugs. Lung cancer (Amsterdam, Netherlands) 2016 Jun . Malapelle Umberto, Morra Francesco, Ilardi Gennaro, Visconti Roberta, Merolla Francesco, Cerrato Aniello, Napolitano Virginia, Monaco Roberto, Guggino Gianluca, Monaco Guglielmo, Staibano Stefania, Troncone Giancarlo, Celetti Ange |
Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative. Oncotarget 2016 Mar . Lim Sun Min, Kim Eun Young, Kim Hye Ryun, Ali Siraj M, Greenbowe Joel R, Shim Hyo Sup, Chang Hyun, Lim Seungtaek, Paik Soonmyung, Cho Byoung Ch |
Molecular and clinicopathological characteristics of ROS1-rearranged non-small-cell lung cancers identified by next-generation sequencing. Molecular oncology 2020 Sep . Cui Meiying, Han Yuchen, Li Pan, Zhang Jianying, Ou Qiuxiang, Tong Xiaoling, Zhao Ruiying, Dong Nan, Wu Xue, Li Wencai, Jiang Guozho |
Genome-wide meta-analysis, fine-mapping and integrative prioritization implicate new Alzheimer's disease risk genes.
Nature genetics 2021 03 53 (3): 392-402. Schwartzentruber Jeremy, Cooper Sarah, Liu Jimmy Z, Barrio-Hernandez Inigo, Bello Erica, Kumasaka Natsuhiko, Young Adam M H, Franklin Robin J M, Johnson Toby, Estrada Karol, Gaffney Daniel J, Beltrao Pedro, Bassett Andr |
Landscape and Clonal Dominance of Co-occurring Genomic Alterations in Non-Small-Cell Lung Cancer Harboring MET Exon 14 Skipping. JCO precision oncology 2021 12 5 . Le Xiuning, Hong Lingzhi, Hensel Chuck, Chen Rongrong, Kemp Haley, Coleman Niamh, Ciunci Christine A, Liu Stephen V, Negrao Marcelo V, Yen Jennifer, Xia Xuefeng, Scheuenpflug Juergen, Stroh Christopher, Juraeva Dilafruz, Tsao Anne, Hong David, Raymond Victoria, Paik Paul, Zhang Jianjun, Heymach John |
Identification of RET fusions in a Chinese multicancer retrospective analysis by next-generation sequencing. Cancer science 2021 Oct . Shi Minke, Wang Weiran, Zhang Jinku, Li Bobo, Lv Dongxiao, Wang Danhua, Wang Sizhen, Cheng Dezhi, Ma Tongh |
RET fusions as primary oncogenic drivers and secondary acquired resistance to EGFR tyrosine kinase inhibitors in patients with non-small-cell lung cancer. Journal of translational medicine 2022 Sep 20 (1): 390. Wang Chunyue, Zhang Zhenlong, Sun Yulan, Wang Song, Wu Mengmeng, Ou Qiuxiang, Xu Yang, Chen Zhiming, Shao Yang, Liu Hong, Hou Peife |
Histomolecular Resistance Mechanisms to First-Line Osimertinib in EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Multicentric Retrospective French Study. Targeted oncology 2022 9 17 (6): 675-682. Akli Assya, Girard Nicolas, Fallet Vincent, Rousseau-Bussac Gaelle, Gounant Valérie, Friard Sylvie, Trédaniel Jean, Dujon Cécile, Wislez Marie, Duchemann Boris, Giroux-Leprieur Etien |
Case report: Dramatic response to pralsetinib in an elderly patient with advanced RET-fusion positive papillary thyroid carcinoma. Frontiers in oncology 2022 12 12 1042525. Nannini Margherita, Repaci Andrea, Ricco Gianluca, Ianni Manuela, Golemi Arber, Maiolo Vincenzo, Ferrari Marco, Natali Filippo, Rizzini Elisa Lodi, Monari Fabio, Solaroli Erica, De Leo Antonio, Maloberti Thais, Pantaleo Maria A, De Biase Dario, Tallini Giovan |
Durable response to low-dose pralsetinib in a renal insufficient patient with NSCLC harboring concurrent CCDC6-RET, LINCO1264-RET, and SEMA5A-RET fusions: A case report. Medicine 2022 12 101 (47): e31480. Gu Linping, Ji Wenxiang, Xu Yunhua, Han Yuchen, Jian Ho |
Molecular genetics of diffuse sclerosing papillary thyroid cancer. The Journal of clinical endocrinology and metabolism 2023 3 . Alswailem Meshael, Alghamdi Balgees, Alotaibi Anwar, Aljomiah Abeer, Al-Hindi Hindi, Murugan Avaniyapuram Kannan, Abouelhoda Mohamed, Shi Yufei, Alzahrani Ali |
TIROSEC: Molecular, Clinical and Histopathological Profile of Papillary Thyroid Carcinoma in a Colombian Cohort. Advances in therapy 2024 1 . Sergio D Cruz-Romero, Sebastián González, José Y Juez, David S Becerra, Ana M Baldión, José A Hakim, Deyanira González-Devia, Sandra Perdomo, Paula A Rodríguez-Urre |
- Page last reviewed:Feb 1, 2024
- Page last updated:Apr 16, 2024
- Content source: